Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.
Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort.
纵向医护人员队列中尼马替韦/利托那韦治疗与 COVID-19 中和抗体滴度的关联
阅读：4
作者：Decker Slade, Xiao Shaoming, Dillen Carly, Schumacher Christina M, Milstone Aaron M, Frieman Matthew, Debes Amanda K
| 期刊： | Open Forum Infectious Diseases | 影响因子： | 3.800 |
| 时间： | 2024 | 起止号： | 2024 Feb 13; 11(2):ofad625 |
| doi： | 10.1093/ofid/ofad625 | 研究方向： | 免疫/内分泌 |
特别声明
1、本文转载旨在传播信息，不代表本网站观点，亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用，必须保留本网站注明的“来源”，并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载，或需洽谈转载稿费等事宜，请及时与本网站联系。
4、此外，如需投稿，也可通过邮箱info@biocloudy.com与我们取得联系。